MDL No. 3180 centralizes federal Dupixent (dupilumab) suits alleging the drug caused, accelerated or unmasked cutaneous T-cell lymphoma.
CTCL is a rare skin lymphoma that can mimic eczema, and the ten questions below track causation, warnings and case growth. Early dispute centers on misdiagnosis versus drug effect and on warning adequacy. Patients with atopic dermatitis treatment followed by later CTCL diagnosis can use these questions to follow timing, records and court direction.
Table of Contents
- Cause, acceleration or unmasking?
- Why does resemblance to eczema matter?
- What does the early human data show?
- Was the warning enough?
- How will the MDL grow and move?
Cause, acceleration or unmasking?
The core allegation covers three paths: new lymphoma, faster disease, or hidden disease revealed during treatment. That distinction matters because treatment history, skin-biopsy timing and prior eczema care point in different directions. Watch 1: Did Dupixent cause new CTCL in a person with no prior lymphoma? Watch 2: Did it accelerate or unmask CTCL that was already present but looked like eczema?.
Why does resemblance to eczema matter?
CTCL can resemble eczema, which can delay biopsy and correct diagnosis. Early rashes, partial response to skin-directed care and changing plaques can therefore look similar before testing. Watch 3: Was the first diagnosis eczema, then revised to CTCL after biopsy? Watch 4: How will the court separate delayed recognition from drug-driven change?.
What does the early human data show?
A 2024 cohort described in the Journal of the American Academy of Dermatology abstract compared about 22,888 dupilumab-treated and 22,871 untreated atopic-dermatitis patients. It reported higher odds of later CTCL diagnosis, OR 4.1003, 95% CI 2.055-8.192.
The result is retrospective, not proof from a prospective randomized trial. Causation, unmasking and warning adequacy therefore remain contested and fact-specific. Watch 5: Will judges admit the odds ratio as reliable support for individual causation? Watch 6: Can plaintiffs prove causation without prospective trial evidence?.
Was the warning enough?
The current U.S. label lists atopic dermatitis, asthma, nasal polyps, eosinophilic esophagitis, prurigo nodularis and COPD uses, with Warnings revised April 2025. It contains no lymphoma or CTCL warning, and no recall has issued.
The Food and Drug Administration listed dupilumab injection and CTCL in its adverse-event monitoring table for October-December 2024 as a potential serious-risk signal. The agency said it was evaluating need for regulatory action. Watch 7: Did the label give adequate notice of a CTCL risk? Watch 8: Will FDA require a label change, communication or other regulatory action?.
How will the MDL grow and move?
The Judicial Panel on Multidistrict Litigation centralized the cases in the District of New Jersey before Judge Zahid N. Quraishi in its transfer order filed June 4, 2026. Parties met July 22 and filed a joint management report Sept. 10, 2026 on leadership and discovery before the Oct.
1, 2026 initial conference. Judicial Panel statistics in the October 1, 2026 pending-dockets report show 38-39 pending actions, up from the initial transfer group. That rise points to expanding federal intake, not a fixed case set. Watch 9: How fast will tag-along filings expand the docket? Watch 10: What will leadership, discovery and expert proof decide first? Keep pharmacy fills, biopsy dates and pathology reports together from the first prescription forward.
- prescription dates, pharmacy fills and prescribing clinician names
- eczema-care visits, photographs, biopsy dates and pathology reports
- CTCL stage, treatment referrals and time off work or school